Introduction
============

According to the European Association of Urology (EAU) guidelines, radical cystectomy (RC) is the standard treatment for localized muscle-invasive and recurrent, high-risk, non-muscle invasive bladder cancer (BC), [@B1]. However, the 5-year survival rate for these patients is a mere 50% [@B2]-[@B6]. Significant efforts are being made to determine predictive parameters for stratifying patients into different prognostic groups, and thus identifying those who will benefit most from neoadjuvant or adjuvant treatment [@B7].

Extravesical disease and a positive lymph node (LN) status are currently the most validated predictors of recurrence and distant metastasis [@B8]-[@B9]. Moreover, a delay of more than three months from diagnosis to RC may influence the oncological outcome negatively [@B10]-[@B11]. Delayed diagnosis would be one possible explanation for women with advanced tumor stage at the initial diagnosis [@B12], resulting in higher rates of extravesical tumor disease at RC, and a delayed acceptance of orthotopic bladder substitution [@B13]-[@B16]. Nevertheless, the functional and long-term oncological outcome, and the postoperative quality of life after ileal neobladder in women were reported to be similar to those in men [@B16]-[@B18]. Irrespective of gender, continent cutaneous diversion or the orthotopic neobladder was associated with lower rates of cancer-specific death [@B19]. However, when adjusted for pathological stage, no cancer-specific survival differences were noted between the ileal conduit and the orthotopic neobladder [@B20]. Gender-related differences in survival outcome after RC remain a debated issue, with contradictory reported data. The female gender was an independent predictor of poor cancer-specific survival in various multicenter studies [@B14],[@B21]-[@B23], including one of the largest with 30.310 patients [@B24]. In contrast, other trials report no gender-specific differences in survival following RC [@B25] despite a higher pathological tumor stage in women than in men, even when matched for different histopathological characteristics [@B25]-[@B28].

In this retrospective study, we reviewed our prospectively maintained 10-year cystectomy database. We evaluated histopathological parameters and gender-specific differences in recurrence-free (RFS), cancer-specific (CSS) and overall survival (OS) among patients who underwent RC and postoperative follow-up at our institution.

Material and Methods
====================

Patients
--------

A single-center cystectomy database [@B29] with data collected prospectively from January 2000 was reviewed retrospectively with the approval of the local ethics committee (study number UN3532; 274/4.4 and AN2015-0085; 348/4.10). The medical records of those patients with localized muscle-invasive or recurrent, high-risk, non-muscle-invasive BC [@B30], who had undergone RC and urinary diversion until March 2016 were reviewed retrospectively. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional ethics committee of the Medical University Innsbruck and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Inclusion and exclusion criteria
--------------------------------

Patients who had undergone cystectomy for benign disease or due to a non-urothelial cancer, those who had received neoadjuvant chemotherapy prior to RC, those who were followed elsewhere postoperatively, and patients with evidence of distant metastasis on standard imaging before surgery were excluded. Finally, 259 patients who had undergone routine follow-up (with a minimum of 6 months) at our outpatient uro-oncology department were included in the study.

Surgery
-------

Standard RC consisted of removal of the bladder, distal ureters and proximal urethra in both genders, including the prostate and seminal vesicles in men, and the adjacent vagina plus uterus in women [@B1],[@B31]. The technique and outcome of "urethra-sparing" surgery in orthotopic ileal neobladder replacement for women have been described previously by our study group [@B16]; the procedure includes the preservation of the sphincter mechanism and most of the lateral vaginal wall [@B16]. Extended bilateral pelvic lymphadenectomy was routinely performed in all patients as recommended and described by the EAU guidelines for muscle-invasive BC [@B1],[@B31]. Intraoperative frozen sections were obtained from the urethra and distal ureters as standard. Tumor-negative frozen sections of the urethral resection margins were required in all patients with orthotopic bladder substitution [@B32].

Follow-up investigations
------------------------

According to our institutional practice, follow-up visits were scheduled every 3 months in the first postoperative year, then at 6-month intervals until the end of the fifth year, and once every year thereafter. Each control visit involved a complete laboratory blood examination with blood gas analysis and PSA in men, analysis of folic acid and vitamin B12 levels starting in the fifth postoperative year, urinary dipstick analysis to exclude urinary tract infection, urinary cytology of voided urine, catheterized urine and urethral washings according to the Papanicolaou classification [@B33], measurement of residual urine in orthotopic ileal neobladders, and standard imaging (chest and abdominopelvic CT scan at every second control, alternated with chest radiography and abdominal ultrasound). Local pelvic recurrence was defined as tumor recurrence in the surgical bed, and distant metastasis as lymphogenic or hematogenic metastatic tumor spread [@B7].

Statistical analysis
--------------------

Patient characteristics of men and women were compared with the Mann-Whitney U test for numerical parameters, the Cochran-Armitage test for trend for ordinal, and Fisher\'s exact test for nominal parameters. One-year, 3-, 5-, and 10-year survival rates and survival curves were calculated using the Kaplan-Meier product-limit estimation approach. Survival curves were compared by the log-rank test. The impact of baseline and histopathological factors on RFS, CSS, and OS was evaluated in univariate as well as multivariate Cox proportional hazards models. To determine whether histopathological factors have different effects for men and women on RFS, CCS and OS, an interaction term between sex and each predictor was included. Statistics were performed with SPSS, version 22.0 (IBM Corp., Armonk, NY), assuming a significance level of α=0.05 (2-tailed). Figures and tables were produced with Microsoft Excel and GraphPad PrismTM6 (GraphPad Software Inc., La Jolla, CA).

Results
=======

Descriptive characteristics
---------------------------

The mean age was 68.3 years (median 69; range 33-88 years), the male/female ratio 4.5:1 (212 men and 47 women). Orthotopic ileal neobladder and cutaneous catheterizable umbilical pouch were performed in 121 (46.7%) patients and incontinent diversions (ileal conduit and ureterocutanostomy) in 138 (53.3%). The mean number of resected pelvic LNs was 19.9 (median, 17; range, 2-56) per patient. Forty-three (16.6%) patients had occult pelvic LN spread at surgery, including 29 with a singular pelvic LN metastasis (pN1), 10 with pN2 and 4 patients with pN3. Extravesical tumor disease (≥pT3 *vs.* pT2: 72.1% *vs.* 20.9%; *p*\<0.001) and advanced age (≥70 *vs.* \<70 years: 62.8% *vs.* 37.2%; *p*=0.046) were the sole significant predictors of a positive LN status in cystectomy specimens. After RC, 40 patients (15.4%) received adjuvant chemotherapy (4 cycles of gemcitabine 1000 mg/m^2^ on days 1, 8 and 15, and cisplatin 70 mg/m^2^ on day 2; 1 cycle = 28 days): 30 (75%) with pT3/T4 disease (13 of them with simultaneous LN metastasis), and 10 (25%) with pathological T2 disease and a concomitant pN+ status.

Oncologic outcome following radical cystectomy
----------------------------------------------

Seventy (27.0%) of 259 patients developed recurrence and 82 (31.7%) of 259 patients died during a mean (range) postoperative surveillance period of 19 (2-265) months. Among those patients with recurrence, local pelvic recurrence was present in 19 (27.1%) of 70 patients, and distant metastasis in 51 (72.9%) of 70 patients, respectively. Overall RFS, CCS and OS were 80.2%, 85.2% and 83.5% at 1 year; 66.7%, 73% and 66.8% at 3 years; 61.1%, 58.2% and 49.5% at 5 years; 39.4%, 52.4% and 30.4% at 10 years, respectively.

**Table [1](#T1){ref-type="table"}** summarizes the descriptive and histopathological patient characteristics according to gender-related differences. Women had a greater propensity for pathological extravesical ≥pT3 disease (53.2% \[25/47\] *vs.* 33.9% \[72/212\], *p*=0.03), and consequently higher rates of heterotopic urinary diversion (72.3% \[34/47\] *vs.* 49.5% \[105/212\], *p*=0.006) than in men.

Nevertheless, the female gender did not independently predict a poorer oncological outcome after RC, neither on univariate nor on multivariate analysis (**Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"})**. Including an interaction term between sex and each histopathological predictor in the Cox regression model, the impact of age, T stage at RC, concomitant CIS, the number of resected LNs at RC, LN status at RC and the type of urinary diversion on RFS, CCS and OS did not differ between men and women.

Univariate and multivariate analysis concerning postoperative survival
----------------------------------------------------------------------

On univariate analysis, pathological tumor stage at RC (hazard ratio \[HR\]=6.63, 95% CI: 3.21-13.69, *p*\<0.001) and continent urinary diversion (HR=0.44, 95% CI: 0.26-0.71, *p*=0.001) were associated with RFS. Advanced tumor stage (HR=4.87, 95% CI: 2.42-9.78, *p*\<0.001), positive LN status (HR=2.08, 95% CI: 1.18-3.67, *p*=0.011), advanced age (HR=1.04, 95% CI: 1.01-1.06, *p*=0.013), and continent urinary diversion (HR=0.35, 95% CI: 0.20-0.59, *p*\<0.001) were predictors of CSS. Moreover, advanced age (HR=1.04, 95% CI: 1.02-1.07, *p*=0.001), extravesical tumor disease (HR=3.04, 95%CI: 1.78-5.20, *p*\<0.001) and continent urinary diversion (HR=0.42, 95%CI: 0.27-0.67, *p*\<0.001) influenced OS significantly (**Table [2](#T2){ref-type="table"}**).

On multivariate analysis, extravesical tumor disease was the sole parameter, independently related to RFS (HR=4.70, 95% CI: 2.09-10.62, *p*\<0.001), CCS (HR=2.77, 95% CI: 1.24-6.18, *p*=0.013) and OS (HR=1.93, 95% CI: 1.03-3.63, *p*=0.041). Besides, orthotopic urinary diversion independently predicted a prolonged RFS (HR=0.36, 95% CI: 0.19-0.67, *p*=0.002), **Table [3](#T3){ref-type="table"}**.

Kaplan-Meier survival curves
----------------------------

Tumor stage, the type of urinary diversion, and positive LN disease were confirmed as the most important predictors of RFS, CSS and OS univariately. For patients with ≤pT1 BC (n=90, 34.7%), 5-year RFS, CCS and OS were 82.9%, 79.6% and 68.1%, respectively. For patients with pT2 BC (n=69, 26.6%), 5-year RFS, CCS and OS were 57.1%, 47.9% and 40.2%, respectively. For patients with extravesical disease (n=97, 37.5%), 5-year RFS, CCS and OS were 42.5%, 42.7% and 35.8%, respectively. Patients with continent urinary diversions had a significantly better RFS (5-year: 73.7% *vs.* 48.3%), CCS (5-year: 72.5% *vs.* 44.9%) and OS (62.6% *vs.* 37.8%) than those who underwent incontinent diversions. Patients with positive LNs (n=39, 15.1%) had a significantly poorer CSS than LN-negative patients (5-year CSS: 64.6% *vs.* 36%).

Kaplan-Meier curves according to the type of urinary diversion (heterotopic *vs.* orthotopic, median: 50 months vs. NE, *p*=0.001 for RFS; median: 45.2 *vs* 85.5 months, *p*\<0.001 for OS) and T stage at RC (NMIBC vs. ≥pT3, *p*\<0.001 for RFS; median: 85.5 vs. 30.3 months, *p*\<0.001 for OS) for RFS and OS are shown in **Figures [1](#F1){ref-type="fig"}A-[1](#F1){ref-type="fig"}D**. Survival analysis revealed a significant negative association between heterotopic urinary diversion (*p*\<0.001), advanced T stage at RC (*p*\<0.001), positive LN disease at RC (*p*=0.049) and CSS (**Figures [2](#F2){ref-type="fig"}A-[2](#F2){ref-type="fig"}C).**

Discussion
==========

BC is marked by numerous gender-specific differences. First, the incidence of bladder cancer is three to four times higher in men than in women [@B34]. Gender-related disparities in the prevalence of urothelial carcinoma of the bladder may partly be explained by potential molecular mechanisms, such as differences in the metabolism of carcinogens via hepatic enzymes [@B35], or the activity of the sex steroid hormone pathway aggravating the BC growth adversely by both, stimulatory and inhibitory effects [@B36]-[@B38]. Androgen receptor (AR) signaling seems to induce bladder carcinogenesis and progression [@B37],[@B39]. Whereas the estrogen receptor (ER)α prevented cancer growth *in vitro* and *in vivo* [@B40], ERβ promoted tumor progression [@B41]. In contrast to the ERα/ERβ pathway, AR signals enhanced the preventive effect of androgen-deprivation therapy (ADT) on bladder cancer recurrence, as AR positivity (HR=0.27; p=0.005) in cancer tissue was an independent predictor of reduced cancer recurrence in patients receiving ADT for two primary urogenital cancers (prostate and bladder), [@B42].

Despite the lower incidence in women than in men, the former was more likely to have an advanced tumor stage at initial presentation as well as at time of RC [@B12],[@B14],[@B24], consequently with lower rates of orthotopic bladder substitution [@B13]-[@B15] and poorer survival rates after RC [@B43]. Although population-based, multicenter cancer registry analyses have confirmed a significantly higher rate of cancer recurrence and cancer-specific mortality in women after RC [@B14],[@B21]-[@B24],[@B44]-[@B45], gender was no independent prognostic factor on propensity score matching, as reported recently [@B46]. In patients with metastatic disease undergoing cisplatin-based chemotherapy, survival outcomes were similar in men and women, even when matched for histopathological factors such as performance status and metastasis [@B47]. In our series, the female gender did not independently predict a poorer RFS, CSS or OS compared to males, although women had a greater propensity for ≥pT3 disease (53.2% *vs.* 33.9%). These data are in line with previous reports, showing that a higher tumor stage in women at the time of surgery did not simultaneously translate into a poor survival outcome [@B26],[@B28]. On Cox regression with sex interaction term, the effect of clinicopathological predictors on RFS, CCS and OS did not differ between genders. However, women had a 20% higher risk of tumor recurrence and all-cause mortality on multivariate analysis, but without statistical significance. This fact may be explained by the limited number of cases included in our observational study (without sample size estimate). Hence these results must be interpreted with caution. Whereas women had similar survival rates when matched for clinicopathological factors, higher tumor and nodal stage was a justified explanation for the poor oncological outcome in women than in an unmatched male control group [@B27]. In contrast, Kluth et al. (2014) mentioned that a higher risk of cancer-specific mortality in females after RC cannot be explained solely by gender-specific disparities in tumor stage, lymph node status or lymphovascular invasion [@B14]. In line with these findings, Dabi et al. confirmed that the female gender independently predicts recurrence and cancer-specific survival, despite comparable histopathological factors between the genders [@B48]. Nevertheless, advanced tumor stage and a positive LN status at RC are known to be the most important predictors of recurrence after RC [@B9]-[@B10],[@B26],[@B49]. In another study by Stein et al (2001), the 5-year RFS in LN-positive patients after RC was a mere 35% [@B2]. In our study, the 5-year CCS was also significantly lower for LN positive than LN negative patients (36.0% *vs.* 64.6%). In our study group, which was well balanced regarding T stage (≤pT1: n=90 \[35.3%\], pT2: n=68 \[26.7%\], ≥pT3: n=97 \[38.0%\]), ≥pT3 stage was the sole independent predictor of a poor RFS (HR=4.70), CCS (HR=2.77) as well as OS (HR=1.93), while positive LN disease (HR=2.08, *p*=0.011) was a predictor of a poor CCS on univariate analysis, but not multivariately.

In addition, we found that orthotopic urinary diversion (HR=0.36, *p*=0.002) was independently related to a favorable RFS. Several authors stated that the risk of urethral recurrence after orthotopic bladder substitution was significantly lower than after heterotopic diversion [@B50]-[@B51]. Moreover, orthotopic or continent bladder replacement was associated with a lower risk of cancer-specific mortality [@B20]. We found a positive tendency towards advanced T stage in heterotopic urinary diversions (≥pT3 *vs.* pT2: 44.1 % *vs.* 24.3%; *p*=0.057), which might explain the poor outcome of heterotopic diversion. Regarding gender-related differences, women had a higher tumor stage at RC, as well as higher rates of heterotopic bladder substitution (72.3% *vs.* 49.5%). A time delay from the initial symptoms to the first urological visit, delayed time to surgery, and longer waiting times, especially in women, have been mentioned as possible reasons for their advanced disease [@B12],[@B21],[@B52]-[@B54]. However, the prognostic impact of such time delay must be evaluated in further trials before drawing any final conclusions [@B46]. Nonetheless, patients who were referred late to the urologist had a higher risk of mortality and poor survival after RC [@B55].

One of the major limitations of the present observational study is its retrospective character and single-center design. Other limitations include a small number of patients, no case number calculations compared to multicenter cancer registries, restricted methods of interpreting statistically independent predictors of postoperative survival, and a certain selection bias in terms of excluding those patients who had received neoadjuvant chemotherapy and those who were followed elsewhere postoperatively.

Conclusions
===========

In conclusion, extravesical tumor disease at the time of surgery was the most important prognostic factor, and thus the sole independent parameter in predicting RFS, CCS, and OS after RC, but without gender-specific differences. This subgroup of patients should be studied in future clinical trials because there is an urgent necessity for effective adjuvant therapy. In women, higher rates of advanced tumor disease and consecutive heterotopic bladder substitution were not necessarily associated with a poorer oncologic outcome compared to men.

Abbrevations
============

Androgen-deprivation therapy=ADT; androgen receptor=AR; bladder cancer=BC; cancer-specific survival=CSS; carcinoma in situ=CIS; estrogen receptor=ER; European Association of Urology=EAU; lymph node=LN; overall survival=OS; radical cystectomy=RC; recurrence-free survival=RFS;
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![**Kaplan-Meier survival curves.** Overall survival (OS) and recurrence-free survival (RFS) in days according to the type of urinary diversion (A, C) and T stage (B, D) and at radical cystectomy. *P* values by log-rank test; \**p*\<0.05; \*\**p*\<0.01; \*\*\**p*\<0.001.](jcav08p3567g001){#F1}

![**Kaplan-Meier survival curves.** Cancer-specific survival (CSS) in days stratified by the type of urinary diversion (**A**), T stage (**B**) and lymph node status (**C**) at radical cystectomy. *P* values by log-rank test; \**p*\<0.05; \*\**p*\<0.01; \*\*\**p*\<0.001.](jcav08p3567g002){#F2}

###### 

Gender-specific differences in descriptive and histopathological factors.

  -----------------------------------------------------------------------------------------------------------------------------
  Parameters                                              Men\                      Women\                    *P*-value
                                                          (n=212)                   (n=47)                    
  ------------------------------------------------------- ------------------------- ------------------------- -----------------
  **Age at surgery**, mean ± SD,                          68.6 ± 9.5, 70.0          67.1 ± 11.2,              0.487\*

  median (range),*years*                                  (37-88)                   69.0 (17-82)              

  **Urinary diversion,** n (%)                                                                                **0.006\*\***

  Heterotopic                                             105 (49.5%)               34 (72.3%)                

  Orthotopic                                              107 (50.5%)               13 (27.7%)                

  **T stage at RC**, n (%)                                                                                    **0.030\*\*\***

  pT0                                                     3 (1.5%)                                            

  pT1/pTIS                                                78 (36.8%)                12 (25.5%)                

  pT2a/2b                                                 59 (27.8%)                10 (21.3%)                

  ≥pT3a                                                   72 (33.9%)                25 (53.2%)                

  **Concomitant CIS at RC**, n (%)                        127 (59.9%)               25 (53.2%)                0.417\*\*

  **R positivity at RC**, n (%)                           11 (5.2%)                 3 (6.4%)                  0.624\*\*

  **Lympho-vascular invasion (LVI) at RC**, n (%)         49 (23.1%)                12 (25.5%)                0.647\*\*

  **Total resected LN count**, mean ± SD median (range)   19.8 ± 10.0 17.0 (2-56)   20.5 ± 12.3 16.0 (7-51)   0.717\*

  **Positive LN count,** mean ± SD, (range)               0.7 ± 3.1, (0-28)         0.6 ± 2.4, (0-15)         0.900\*

  **N stage at RC**, n (%)                                                                                    1.000\*\*

  pN0                                                     177 (83.5%)               39 (83.0%)                

  pN+                                                     35 (16.5%)                8 (17.0%)                 

  **Recurrence**, n (%)                                   55 (25.9%)                15 (31.9%)                0.468\*\*

  **Follow-up after RC,** median (range), *months*        20.0 (6-265)              16.0 (6-117)              0.423\*
  -----------------------------------------------------------------------------------------------------------------------------

*P*-values were calculated by Mann-Whitney *U* test\*, Fisher\'s exact test\*\* and Cochran-Armitage test for trend\*\*\*.

*Abbrevations:* Carcinoma in situ (CIS), lymph node (LN), radical cystectomy (RC).

###### 

Univariate Cox regression model evaluating the association between histopathological, baseline characteristics and recurrence-free survival (RFS), cancer-specific survival (CSS) and overall survival (OS) after RC.

  Predictors                Recurrence-free survival   Cancer-specific survival   Overall survival                                                       
  ------------------------- -------------------------- -------------------------- ------------------ ------ ----------- ------------- ------ ----------- -------------
  **Gender**                                                                                                                                             
  Men                       1.00                                                                     1.00                             1.00               
  Women                     0.70                       0.39-1.24                  0.225              0.93   0.49-1.73   0.810         1.03   0.59-1.81   0.914
  **Age\***                 1.01                       0.98-1.03                  0.461              1.04   1.01-1.06   **0.013**     1.04   1.01-1.07   **0.001**
  **T stage**                                                                                                                                            
  pT1/CIS                   1.00                                                                     1.00                             1.00               
  pT2a/2b                   3.00                       1.35-6.69                  **0.007**          2.44   1.11-5.40   **0.027**     1.66   0.88-3.12   0.115
  ≥pT3a                     6.63                       3.21-13.69                 **\<0.001**        4.87   2.42-9.78   **\<0.001**   3.04   1.77-5.20   **\<0.001**
  **Concomitant CIS**       0.65                       0.41-1.04                  0.073              0.68   0.42-1.10   0.117         0.72   0.47-1.10   0.130
  **LN status at RC**                                                                                                                                    
  pN-                       1.00                                                                     1.00                             1.00               
  pN+                       1.77                       0.99-3.16                  0.052              2.08   1.18-3.67   **0.011**     1.60   0.94-2.72   0.086
  **Resected LN count\***   1.00                       0.97-1.03                  0.981              0.99   0.96-1.02   0.675         0.99   0.96-1.02   0.427
  **Urinary diversion**                                                                                                                                  
  Heterotopic               1.00                                                                     1.00                             1.00               
  Orthotopic                0.44                       0.26-0.71                  **0.001**          0.35   0.20-0.59   **\<0.001**   0.42   0.27-0.67   **\<0.001**

^\*^Cox regression with continuous covariate

###### 

Multivariate Cox regression model evaluating the association between histopathological, baseline characteristics and recurrence-free survival (RFS), cancer-specific survival (CSS) and overall survival (OS) after RC.

  Predictors                Recurrence-free survival   Cancer-specific survival   Overall survival                                                     
  ------------------------- -------------------------- -------------------------- ------------------ ------ ----------- ----------- ------ ----------- -----------
  **Gender**                                                                                                                                           
  Men                       1.00                                                                     1.00                           1.00               
  Women                     1.20                       0.58-2.47                  0.628              1.05   0.47-2.32   0.905       1.22   0.60-2.47   0.582
  **Age\***                 0.98                       0.95-1.01                  0.169              1.01   0.98-1.05   0.527       1.02   0.99-1.05   0.265
  **T stage**                                                                                                                                          
  pT1/CIS                   1.00                                                                     1.00                           1.00               
  pT2a/2b                   3.11                       1.31-7.41                  **0.010**          1.98   0.82-4.78   0.128       1.44   0.71-2.94   0.311
  ≥pT3a                     4.70                       2.08-10.62                 **\<0.001**        2.77   1.24-6.18   **0.013**   1.93   1.03-3.63   **0.041**
  **Concomitant CIS**       0.68                       0.39-1.18                  0.173              0.80   0.44-1.47   0.477       0.74   0.44-1.26   0.269
  **LN status at RC**                                                                                                                                  
  pN-                       1.00                                                                     1.00                           1.00               
  pN+                       1.19                       0.61-2.37                  0.602              1.59   0.81-3.13   0.180       1.20   0.64-2.26   0.568
  **Resected LN count\***   0.99                       0.96-1.02                  0.645              0.99   0.96-1.03   0.795       0.99   0.96-1.02   0.650
  **Urinary diversion**                                                                                                                                
  Heterotopic               1.00                                                                     1.00                           1.00               
  Orthotopic                0.36                       0.19-0.67                  **0.002**          0.54   0.27-1.05   0.068       0.62   0.36-1.09   0.100

^\*^Cox regression with continuous covariate
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